Virus-Like Particle (VLP) Vaccines
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 5294
Special Issue Editors
Interests: HIV
Special Issue Information
Dear Colleagues,
An effective HIV vaccine design remains one of the biggest challenges facing the scientific community today. In fact, after more than 30 years of intensive research in this field, we still do not have a protective vaccine capable of stopping HIV transmission.
Traditional vaccines based on live attenuated viruses have been ruled out for HIV and other viruses for biosafety reasons. In some viruses, such as HIV, many of the vaccine prototypes investigated thus far have shown difficulty in generating effective broadly neutralizing antibodies and cytotoxic T-cell immune responses to primary HIV isolates.
Virus-like particles (VLPs) have been shown to be safe to administer to animals and humans. In addition, VLPs have demonstrated the ability to stimulate both innate and adaptive immune responses. Moreover, their particulate structure favors absorption by antigen-presenting cells. These intrinsic immunological characteristics of VLPs, augmented by their self-adjuvant properties and demonstrated success as products to date, suggest potential for broad impact in the coming years.
This Special Issue aims to collect research articles, brief reports and communications on "virus-like particle (VLP) vaccines" in order to promote the knowledge and discussion about the various VLP formulations developed and modifications aimed at improving antigen display versatility, efficacy and stability. We look forward to receiving your contributions.
Dr. Eloisa Yuste
Prof. Dr. James Binley
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV
- virus-like particles
- humoral immune response
- cellular immune response
- stability
- broadly neutralizing antibodies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.